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ABSTRACT
Objectives Despite advances in systemic lupus
erythematosus (SLE) treatment, many patients suffer from
the disease and side effects. Atacicept is a fusion protein
that blocks B-lymphocyte stimulator and a proliferation-
inducing ligand, which are increased in patients with SLE.
Methods In this double-blind, placebo-controlled study,
patients with moderate-to-severe SLE were randomised to
atacicept 75 mg or atacicept 150 mg administered
subcutaneously, or placebo twice-weekly for 4 weeks,
then weekly for 48 weeks. Primary and secondary efﬁcacy
measures were the proportion of patients experiencing at
least one ﬂare of British Isles Lupus Assessment Group A
or B, and time to ﬁrst ﬂare, respectively.
Results Enrolment in the atacicept 150 mg arm was
discontinued prematurely due to two deaths. In the
intention-to-treat population (n=461), there was no
difference in ﬂare rates or time to ﬁrst ﬂare between
atacicept 75 mg and placebo. Analysis of patients treated
with atacicept 150 mg suggested beneﬁcial effect versus
placebo in ﬂare rates (OR: 0.48, p=0.002) and time to
ﬁrst ﬂare (HR: 0.56, p=0.009). Both atacicept doses were
associated with reductions in total Ig levels and anti-
dsDNA antibodies, and increases in C3 and C4 levels.
Most treatment-emergent adverse events were mild or
moderate.
Conclusions There was no difference between atacicept
75 mg and placebo for ﬂare rate or time to ﬁrst ﬂare.
Analysis of atacicept 150 mg suggested beneﬁt.
Trial registration number EudraCT: 2007-003698-
13; NCT00624338.
INTRODUCTION
Morbidity and mortality have improved consider-
ably for patients with systemic lupus erythematosus
(SLE) in the past 50 years; the 4-year survival rate
of 50% in 1950 is now a 10-year survival rate of
90%.1 However, some patients continue to die pre-
maturely, suffer signiﬁcant damage and have a
reduced quality of life.1 A recent study2 of patients
with lupus nephritis in a lupus cohort followed for
30 years found no change in the risk of the devel-
opment of end-stage disease over this time and
only a marginal improvement in mortality. The
authors suggested that these results indicate that
the beneﬁts of conventional therapies (meaning
steroids and immunosuppressives) have been maxi-
mised. The need to identify novel therapies with
improved risk/beneﬁt ratios remains, particularly
for those responding inadequately to this approach.
The use of biological drugs targeting key molecules
or cells has yet to revolutionise the treatment of
patients with SLE.
Several strategies have targeted B-lymphocytes
due to their important role in autoantibody pro-
duction, autoantigen presentation and immune dys-
regulation through cytokine secretion.3 The notion
of directly attacking B-cells using rituximab (which
binds the CD20 molecule on B-cell surfaces)
seemed attractive, with numerous case series
reporting success in ‘hard-to-treat’ SLE patients.4
However, subsequent controlled trials of rituximab
were disappointing.5 6 An alternative approach to
B-cell-directed therapy involves using a monoclonal
antibody to a B-cell-activating factor known as
B-lymphocyte stimulator (BLyS), a cytokine that
promotes B-cell proliferation and differentiation. In
two randomised, controlled Phase III trials,7 8
anti-BLyS (belimumab) plus standard-of-care (SOC)
therapy demonstrated statistically signiﬁcant beneﬁt
compared with SOC alone in patients with primar-
ily cutaneous and musculoskeletal manifestations of
SLE. Consequently, the drug was approved by the
Food and Drug Administration and the European
Medicines Agency.
Atacicept is a fusion protein containing the extra-
cellular, ligand-binding portion of the receptor TACI
(transmembrane activator and calcium-modulator
and cyclophilin-ligand (CAML)-interactor) and the
modiﬁed Fc portion of human IgG that blocks BLyS
(like belimumab) and another B-cell activating factor,
known as a proliferation-inducing ligand (APRIL).9
BLyS and APRIL levels are increased in patients with
SLE,10 suggesting that dual blockade by atacicept
may be more potent than blockading BLyS alone and
has the beneﬁt of targeting long-lived plasma cells in
addition to B cells.11 Here, we report the results of a
randomised Phase II/III trial of atacicept that sought
to determine the efﬁcacy and safety of atacicept in
the prevention of ﬂares in SLE.
PATIENTS AND METHODS
Study design
This was a 52-week, randomised, double-blind,
placebo-controlled, parallel-group, multicentre
trial (EudraCT: 2007-003698-13; NCT00624338)
of atacicept in patients who originally had
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moderate-to-severe SLE exempting those with renal or central
nervous system (CNS) disease. Informed consent, trial protocol
and all substantial amendments were obtained from all patients
in accordance with the relevant human patients’ Institutional
Review Boards. The trial was conducted in accordance with the
protocol, the International Conference on Harmonisation (ICH)
guideline for Good Clinical Practice (GCP) and applicable local
regulations as well as with the Declaration of Helsinki.
In order to evaluate better the effect of atacicept on the devel-
opment of new ﬂares, patients were administered prednisone or
equivalent corticosteroid starting at 60 mg daily for 2 weeks
(for patients with one or more British Isles Lupus Assessment
Group (BILAG) A scores) and starting at 20 mg/day daily for
patients with one or more BILAG B scores but no A scores. The
steroid dosage was reduced from the start of week 3 in all
patients (according to protocol) down to 7.5 mg daily at week
10. Patients achieving BILAG C or D scores in all systems at
week 10 without any new A or B scores by week 12 (n=461)
while on 7.5 mg of daily prednisone for weeks 11 and 12 were
randomised to receive subcutaneous injection of atacicept 75 or
150 mg or matching placebo in a 1:1:1 ratio. Thus only patients
with essentially inactive disease were eligible for randomisation.
The dose of prednisone or equivalent remained constant during
the study unless patients developed a postrandomisation ﬂare.
Flares were predeﬁned as having an adjudicated BILAG A or B
score due to items that were new or worse in any of the eight
organ systems during treatment or imputed for subjects who
had premature treatment discontinuation as deﬁned in the statis-
tical analysis plan. Randomisation was stratiﬁed by ‘black’,
‘white’ or ‘other’ and by BILAG category (A or B) at screening.
Investigational medicinal drug was administered twice-weekly
for 4 weeks and then once-weekly for the remaining 48 weeks.
Patients were followed up for 24 weeks after the last dose of
trial medication. A schematic diagram of the trial design as
shown in the protocol is presented in online supplementary
ﬁgure S1.
Medical history was obtained at study entry and a 4-weekly
physical examination took place, with additional assessments at
week 10 during the steroid reduction protocol and 2 weeks
postrandomisation. Haematological and serum chemistry pro-
ﬁles were performed concomitantly and were evaluated using
the Common Toxicity Criteria of the National Cancer Institute.
Efﬁcacy was assessed 4-weekly, primarily through a BILAG
2000 assessment 13.
The investigators were trained in the use of the BILAG assess-
ment index and had to pass a written examination before enrol-
ling patients. An adjudication committee regularly and carefully
reviewed the patient’s assessments looking for inconsistencies
that could be checked locally.
Inclusion and exclusion criteria
Patients aged ≥16 years (≥18 years old in Switzerland,
Lithuania, Lebanon, Poland, Bulgaria, and site 120 in Australia)
with active SLE deﬁned by category A or B manifestations
(excluding a single B score in haematology) on the BILAG
index12 13 that required a change in steroid dose were included.
All patients had to have a diagnosis of SLE satisfying at least 4
of the 11 American College of Rheumatology classiﬁcation cri-
teria14 and updated in 1997,15 with a disease duration of
≥6 months. Patients had to be positive for antinuclear antibody
(ANA) (HEp-2 ≥1:80) or anti-double-stranded DNA (dsDNA)
antibodies (≥30 IU/L). Patients could be included if they had
been on stable doses of azathioprine (≤3 mg/kg/day), hydroxy-
chloroquine (≤400 mg/day), chloroquine (≤250 mg/day) or
methotrexate (≤25 mg/week) for 2 months prior to screening
(these patients remained on the same medication and dosage
throughout the trial unless the drug was stopped due to
toxicity).
Patients were excluded if they had taken any cyclophospha-
mide, mycophenolate mofetil (MMF), calcineurin inhibitors,
leﬂunomide, 6-mercaptopurine or thalidomide within 3 months
of screening. Other exclusion criteria included a history of treat-
ment with rituximab, abatacept or belimumab, and participation
in any interventional trial within the last 28 days or 5 half-lives
(whichever was longer) from the trial. Patients with severe CNS
lupus, congestive heart failure, a history of cancer, other than
treated basal cell or squamous cell carcinoma of the skin or
active moderate-to-severe glomerulonephritis (urinary protein:
creatinine ratio >1.0 mg/mg and/or haematuria, or glomerular
ﬁltration rate <50 mL/min/1.73 m2), a history of recurrent or
active infections such as HIV, tuberculosis, hepatitis B virus, or
hepatitis C virus and a history of demyelinating disease, for
example, multiple sclerosis or optic neuritis, were excluded.
Primary and secondary outcome measures
The primary outcome measure was the proportion of patients
experiencing at least one ﬂare of BILAG A or B, as deﬁned by
the BILAG index13 during the 52-week trial period. Premature
discontinuation of study drug was imputed as a ﬂare.
The main secondary endpoint was time to ﬁrst ﬂare during
the treatment period. Other endpoints included the proportion
of patients with a BILAG A or B ﬂare within the ﬁrst or second
24 weeks after randomisation, corticosteroid exposure postran-
domisation, ordinal response categories for BILAG ﬂares,
changes from baseline in titres of anti-dsDNA antibodies and
complement levels (C3 and C4).
The adjudication committee reviewed all BILAG data, includ-
ing all renal and haematology results, whether attributed
to lupus or not, but were blinded to immunology results
(Ig, complement and B-cell levels), and treatment changes.
Pharmacodynamics
The pharmacodynamics of the study medication were assessed
by measuring serum levels of immunoglobulins (total IgG, IgM,
IgA), C3 and C4 complement and anti-dsDNA antibodies.
Antinuclear (ANAs) and anti-dsDNA antibodies were measured
using the ELISA test system.
Safety assessments
Safety was evaluated through the nature, incidence and severity
of adverse events (AEs) and clinical laboratory abnormalities,
and through assessment of any changes in clinical laboratory
parameters, vital signs, ECGs and physical examination ﬁndings.
Patients were tested for antibodies to atacicept at baseline and at
the ﬁnal poststudy visit 24 weeks after the last dose using bridg-
ing ELISA based on streptavidin precoated plates. Changes in
antibody titres to pneumococcus toxoid, tetanus toxoid and
diphtheria toxoid were evaluated. Titres of antibodies to
pneumococcus, tetanus toxoid and diphtheria toxoid were mea-
sured at baseline and at week 52/early termination.
Statistical analyses
Data were analysed for the following populations:
intention-to-treat (ITT): all randomised subjects; modiﬁed ITT
(mITT): all randomised subjects who received at least one dose
of study medication (this was also the Safety Analysis Set); and
potential completer (PC): all subjects who were randomised
≥52 weeks prior to atacicept 150 mg arm termination. More
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details of the statistics used are provided in the accompanying
supplementary materials.
RESULTS
Study population
Of the 1007 patients enrolled, 546 failed screening, 461 were
randomised (ITT analysis set) into three treatment groups and
455 of these received trial medication (mITT and safety analysis
sets) (ﬁgure 1). Online supplementary table S1 summarises the
reasons for screen failure, and online supplementary table S2
shows the reasons for discontinuation by treatment group
during the treatment period.
Enrolment in the atacicept 150 mg arm was discontinued pre-
maturely due to two deaths from pneumonias complicated by
pulmonary haemorrhage. When treatment was discontinued,
62/144 patients in this arm had completed 52 weeks of treat-
ment; 27 other patients had already been withdrawn for various
reasons and, in the remaining 55 patients, treatment was
stopped early as a safety precaution. Patients in the other two
groups completed the protocol. The baseline characteristics
between patients that completed the protocol and the PC popu-
lation were similar. In total, 111 patients in the placebo group
and 112 patients in the atacicept 75 mg group completed
52 weeks of treatment. Subjects who discontinued treatment
prematurely, or who were randomised but not treated (three in
the placebo group, two in the atacicept 75 mg group and one in
the atacicept 150 mg group), were analysed as ﬂared.
Demographic and baseline data were comparable across all
treatment groups (table 1, see online supplementary table S3).
More than 90% of patients in each treatment group were
female. Approximately 70% in each treatment group were
white, 18–21% were Asian and another 6–7% were classiﬁed as
‘other’. In the PC analysis set, 63–65% of patients in each treat-
ment group were white, 21–26% were Asian and another
7–12% were classiﬁed as ‘other’. Less than 5% of patients in
any treatment group were classiﬁed as black. Randomisation
was stratiﬁed by disease severity and there was a similar number
of patients with ﬂares A or B across arms. The overwhelming
number of patients with A or B ﬂares were in the musculoskel-
etal or mucocutaneous systems.
Efﬁcacy
Primary endpoint
The primary objective was not met by the atacicept 75 mg
group, which showed no beneﬁt for atacicept 75 mg compared
with the SOC plus placebo group in the ITT analysis set (ﬂare
rates of 58% and 54%, respectively; OR 1.15 (0.73 to 1.80),
p=0.543) (ﬁgure 2A).
Post hoc analysis of atacicept 150 mg in the ITT analysis set
suggested a beneﬁcial effect of atacicept 150 mg versus placebo
(ﬂare rate 37% and 54%, respectively; OR 0.48 (0.30 to 0.77),
p=0.002). Discontinuations due to arm termination were not
imputed as ﬂares. This analysis of the atacicept 150 mg group
was undermined by the occurrence of two deaths in this group
(see below). To address this confounding effect, we performed
analyses of the primary endpoint in the PC population. PC
population analysis paralleled the results of the ITT analysis.
Speciﬁcally, there was no signiﬁcant beneﬁt of atacicept 75 mg
compared with placebo (ﬂare rate 58% and 60%, respectively;
OR 0.89 (0.48 to 1.67), p=0.724). Atacicept 150 mg did show
a beneﬁcial effect versus placebo (ﬂare rate 43% and 60%,
respectively; OR 0.49 (0.26 to 0.92), p=0.027) (ﬁgure 2B).
Secondary endpoints
For the main secondary efﬁcacy endpoint, time to ﬁrst ﬂare,
there was no statistically signiﬁcant difference between atacicept
75 mg and placebo for the ITT analysis set (HR 0.98 (0.69 to
1.40), p=0.929) (ﬁgure 2C). There was no signiﬁcant difference
in time to ﬁrst ﬂare in the placebo and atacicept 75 mg arms
(HR (95% CI) 0.83 (0.53 to 1.29); p=0.404) for the PC ana-
lysis set (ﬁgure 2D).
The post hoc analysis showed atacicept 150 mg was associated
with a signiﬁcant delay in time to ﬁrst ﬂare for the ITT analysis
set (HR 0.56 (0.36 to 0.87), p=0.009 (see online supplemen-
tary ﬁgure S2)). Patients in the PC population treated with an
atacicept 150 mg dose had a 59% lower risk of having a new
BILAG A or B ﬂare over the 52-week treatment period than
patients in the SOC plus placebo group (HR 0.41 (0.24 to
0.70), p=0.001, respectively) (ﬁgure 2D). Within the ﬁrst
24 weeks of treatment, there was no signiﬁcant difference across
treatment groups for the proportions of ﬂares (BILAG A or B).
However, from weeks 24 to 52 of treatment, for those who
completed the ﬁrst 24-week treatment period, the atacicept
150 mg group showed a signiﬁcant reduction in ﬂare rate com-
pared with the placebo group (16% vs 36% in the mITTanalysis
set and 15% vs 39% in the PC population). The mITT popula-
tion was prespeciﬁed in the statistical analysis plan, but not in
the protocol.
For ordinal response categories of BILAG ﬂare, the odds of
having a ﬂare with lower severity (ordered from low to high: no
A or B and completed treatment, no A and at least one B and at
least one A (with or without B)) were higher for atacicept 75 mg
(35 (48.6%), 29 (40.3%), 8 (11.1%); OR 1.20 (0.64 to 2.24),
p=0.577) and signiﬁcantly high for atacicept 150 mg (46
(70.8%), 16 (24.6%), 3 (4.6%); OR 3.24 (1.61 to 6.52),
p<0.001) versus SOC and placebo in the PC population.
The reduction in the proportion of patients with a new ﬂare
as deﬁned in the primary endpoint (at least one BILAG A or B)
was observed in the eight systems evaluated in the atacicept
150 mg group as compared with atacicept 75 mg or placebo
with a more marked decrease in the atacicept 150 mg group
compared with the placebo and atacicept 75 mg groups in the
musculoskeletal (18.1%, 21.7% and 9.0%) and mucocutaneous
(17.5%, 21.0% and 9.0%) organ systems (placebo, atacicept
75 mg and atacicept 150 mg groups, respectively). Flares during
the treatment period are summarised by organ system in online
supplementary table S4.
A dose-dependent decrease was noted in the proportion of
subjects in the PC analysis set who had at least one increase in
corticosteroid dose to ≥20 mg/day. Thus, high dose of prednis-
one was given to 32%, 27% and 12% of patients in the
placebo, atacicept 75 mg and atacicept 150 mg groups,
respectively.
Pharmacodynamics
Analysis of total Ig levels revealed decreases in response to the
corticosteroid treatment during the screening period followed
by further atacicept treatment-associated decreases in a dose-
dependent manner (ﬁgure 3). Over the 52-week treatment
period, for treatment completers (all 285 subjects who com-
pleted 52 weeks of trial treatment), the median IgG concentra-
tion declined from baseline by 30% in the atacicept 75 mg arm
and 38% in the atacicept 150 mg arm, compared with a 3%
increase in the controls. Declines were also noted in IgA (53%
and 58% decline, respectively, compared with a 2% increase in
the controls) and IgM (66% and 69% decline, respectively,
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compared with a 1% decline in the controls). During screening
according to the steroid reduction protocol, serum IgG showed
a median percent decrease of approximately 8.5% across
groups.
Treatment with atacicept also reduced the median concentra-
tion of anti-dsDNA antibodies (ﬁgure 4A). For those
anti-dsDNA positive at screening (≥30 IU/mL), anti-dsDNA
antibody levels were reduced from baseline by 31% in the
75 mg arm and 38% in the 150 mg arm versus a 14% increase
in the control arm.
In both the ITT and the treatment completer analysis, ataci-
cept was associated with increases in C3 levels at week 52 (least
squares (LS) mean change vs placebo: 0.076 (p<0.001) and
0.138 (p<0.001) for atacicept 75 mg and atacicept 150 mg,
respectively). This effect was more pronounced for patients with
low levels at screening (<0.9 g/L). Thus, median changes in C3
from baseline to week 52 were 4.1%, 7.2% and 15.4% for
placebo, atacicept 75 mg and atacicept 150 mg, respectively
(ﬁgure 4B). Similar results were observed for C4 levels (ﬁgure
4C). LS mean changes versus placebo at week 52 were 0.046
and 0.066 for atacicept 75 mg and atacicept 150 mg (p<0.001
for both), respectively. In patients with low levels of C4 at
screening (<0.1 g/L), median changes in C4 from baseline to
week 52 were −0.4%, 42.7% and 49.5% for placebo, atacicept
75 mg and 150 mg, respectively. Following cessation of treat-
ment, levels of total Ig, C3, C4 and anti-dsDNA returned
towards baseline. There was also a reduction in B-cells and
plasma cells.
Safety
Of 455 patients in the Safety Analysis set, 374 patients (82.2%)
experienced one or more adverse events emerging during treat-
ment (TEAEs) during the study (52-week treatment period and
24-week follow-up period), and 80 patients (17.6%) experi-
enced at least one serious adverse event (SAE) during the treat-
ment phase and/or follow-up phase (table 2).
Figure 1 Patient disposition.
*Includes potential completer (PC)
population, n=81; **Includes PC
population, n=84; †Includes PC
population, n=81.
Table 1 Patient demographics and baseline disease characteristics
Intention-to-treat population*
Placebo
n=157
Atacicept 75 mg
n=159
Atacicept 150 mg
n=145
Mean age (range), years 39.0 (20–79) 39.1 (16–75) 39.0 (17–69)
Female, n (%) 148 (94.3) 148 (93.1) 134 (92.4)
Race, n (%)
White 114 (72.6) 114 (71.7) 102 (70.3)
Black 3 (1.9) 5 (3.1) 2 (1.4)
Asian 30 (19.1) 29 (18.2) 31 (21.4)
Other 10 (6.4) 11 (6.9) 10 (6.9)
Disease severity at screening, n (%)
≥1 BILAG A 31 (19.7) 32 (20.1) 31 (21.4)
Only BILAG B 126 (80.3) 127 (79.9) 114 (78.6)
Potential completer population
Placebo
n=81
Atacicept 75 mg
n=84
Atacicept 150 mg
n=81
Mean age (range), years 37.1 (20–63) 39.2 (16–75) 38.5 (18–69)
Female, n (%) 76 (93.8) 79 (94.0) 73 (90.1)
Race, n (%)
White 52 (64.2) 53 (63.1) 53 (65.4)
Black 1 (1.2) 3 (3.6) 1 (1.2)
Asian 19 (23.5) 18 (21.4) 21 (25.9)
Other 9 (11.1) 10 (11.9) 6 (7.4)
Disease severity at screening, n (%)
≥1 BILAG A 18 (22.2) 19 (22.6) 18 (22.2)
Only BILAG B 63 (77.8) 65 (77.4) 63 (77.8)
*Patient demographics were similar in the intention-to-treat and modified intention-to-treat populations.
BILAG, British Isles Lupus Assessment Group.
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Figure 2 Analysis of the primary and the main secondary outcome measure. (A) Proportion of patients who experienced a ﬂare during the
52-week treatment period in the ITT population; (B) proportion of patients who experienced a ﬂare during the 52-week treatment period in the
potential completer analysis; (C) time to ﬁrst new ﬂare in the ITT population; (D) time to ﬁrst new ﬂare in the potential completer population. ITT,
intention-to-treat.
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The most commonly reported TEAEs were upper respiratory
tract infection (17.1%), headache (15.6%) and urinary tract
infection (14.1%). In general, incidence rates for patients in the
placebo group tended to be lower than those for the atacicept
75 mg and atacicept 150 mg groups, with the exception of diar-
rhoea, sinusitis, inﬂuenza, hypertension and hypotension, which
occurred in similar frequency. Of the 455 patients in the Safety
Analysis set, most TEAEs were mild or moderate. The most fre-
quently reported SAEs were infections and infestations, includ-
ing pneumonia (10 patients: 2 patients in the placebo group, 5
patients in the atacicept 75 mg group and 3 patients in the ataci-
cept 150 mg group). Five subjects receiving atacicept (two
subjects receiving 75 mg, and three subjects receiving 150 mg)
reported SAEs of pneumonia for which the events were assessed
by the investigators as related to trial treatment. Two patients
randomised to the atacicept 150 mg treatment group died. A
22-year-old male with SLE in the Philippines died from acute
respiratory failure due to alveolar haemorrhage secondary to
possible leptospirosis. This patient also suffered from an overlap
syndrome with features of scleroderma, complicated by a
history of recurrent infected digital ulcers. The second patient, a
30-year-old female in Argentina, died from pneumococcal pneu-
monia and alveolar haemorrhage secondary to lupus. These
patients were treated with atacicept for 42 and 33 weeks,
Figure 3 Change from baseline
(median) in (A) IgG, (B) IgA and (C)
IgM levels (treatment completer
population). IgG, immunoglobulin G;
IgA, immunoglobulin A; IgM,
immunoglobulin M.
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respectively, and were receiving prednisone 20 and 7.5 mg daily
and hydroxychloroquine, respectively, for lupus at the time of
the event. Both patients experienced reductions in their total
IgG and IgM levels, but the IgG levels remained above 14.6 g/L
(normal range approximately 6–18 g/L), and the IgM levels
remained above 0.34 g/L. The trial’s Independent Data
Monitoring Committee (IDMC) recommended that the ataci-
cept 150 mg dose group be discontinued.
Protective immunity to common pathogens was investigated.
Vaccine titres against tetanus toxoid, diphtheria and pneumococ-
cus were assessed at baseline and week 52 (or early termin-
ation). With regards to pneumococcal and tetanus titres, 1 in 30
(3.3%) placebo-treated patients had loss of protective titre
status, whereas 1 in 10 (10%) atacicept-treated patients lost pro-
tective titre status. Median percent titre changes from baseline
at week 52 for atacicept 75 mg, atacicept 150 mg and placebo,
respectively, were −33.3%, −34% and 0 for tetanus toxoid;
−21.1%, −11% and 0 for diphtheria; −29%, −30% and +2%
for pneumococcus.
Immunogenicity was assessed by analysis of samples predose
and postdose. Three patients in the atacicept 150 mg group
showed measurable antibodies to atacicept at the week 24
follow-up visit.
DISCUSSION
This study was designed to assess whether blockade of two
B-cell activating factors, BLyS and APRIL, using atacicept could
prevent ﬂares in patients that had had lupus disease activity
treated with (or that had responded to) a course of corticoster-
oids. Two fatal infections occurred in the 150 mg atacicept arm.
A contributing role of atacicept could not be excluded, resulting
in a premature termination of this group. Consequently, only
the 75 mg and the placebo arm could be assessed for the
primary endpoint analysis. There was no difference in the
Figure 4 Median change from
baseline in anti-dsDNA and
complement in the treatment
completer population (all 285 subjects
who completed 52 weeks of trial
treatment). (A) Change in anti-dsDNA
in patients positive at screening
(≥30 IU/mL); (B) change in C3 in
patients with below normal C3 levels
at screening (<0.9 g/L); (C) change in
C4 in patients with below normal C4
levels at screening (<0.1 g/L).
Anti-dsDNA, anti-double-stranded
DNA.
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adjudicated ﬂare rate between the placebo and the 75 mg ataci-
cept arm.
Post hoc analysis of the primary endpoint in the ITT analysis
set suggested a beneﬁcial effect from the atacicept 150 mg
regime since patients in this arm did show a statistically signiﬁ-
cant reduction the proportion of patients with BILAG ﬂare A or
B ﬂare compared with placebo (36.6% vs 54.1%, OR 0.48
(0.30 to 0.77); p=0.002). The high-dose treatment was asso-
ciated with a signiﬁcantly delayed time to ﬁrst ﬂare (BILAG A or
B) compared with placebo (HR 0.56, p=0.009). Among all
patients who completed treatment prior to discontinuation of
the 150 mg arm (81–84 patients per group), there was a distinct
reduction in the ﬂare rate and an increase in the time to ﬂare
for patients in the 150 mg arm compared with that seen in
either the placebo or the 75 mg arm.
Atacicept may have steroid-sparing beneﬁt. There was a dose-
dependent decrease in the proportion of subjects who had at
least one increase in corticosteroid dose to ≥20 mg/day. In spite
of the early termination of the 150 mg arm, there remains a
strong suggestion that the higher dose of atacicept was effective.
Serological improvements were seen in both atacicept arms.
Both doses of atacicept reduced anti-dsDNA antibodies to a
similar extent, so this does not explain the apparent clinical
responses to the 150 but not 75 mg dose. The link between
dsDNA antibodies and clinical activity is far from absolute.16
The beneﬁcial effect on C3 (and to a lesser extent) C4 is more
clear-cut in those treated with 150 mg atacicept, but why the
beneﬁcial clinical threshold appears at 150 vs 75 mg of atacicept
remains incompletely understood.
The indication of possible efﬁcacy must be weighed against
the two deaths due to infection in the 150 mg arm. Thus, in the
ﬁrst belimumab trial7 in a similar range of non-renal clinical fea-
tures patient population (Belimumab in Subjects with Systemic
lupus erythematosus (BLISS)-52), there were nine deaths among
865 patients (1%), followed by three deaths among 819 patients
(0.4%) in the BLISS-76 trial.8 In the phase IIb blisibimod trial
in 547 patients with SLE, there were seven deaths, three in
placebo and four among three active treatment arms.17
As both deaths in the current trial occurred in the 150 mg
arm, the IDMC recommended discontinuation of treatment in
this study arm as a cautionary measure. The infections in these
two patients were not associated with hypogammaglobulinae-
mia. Treatment with atacicept has previously been found to
reduce B-cells and Ig levels without signiﬁcant adverse events in
a dose-escalating Phase Ib study in mild/moderate non-renal
lupus.9 A reduction in B-cells, plasma cells and the mean IgG
concentration in the atacicept groups was observed in this study,
with a 30% reduction in the 75 mg arm and a 38% reduction in
the 150 mg arm, compared with a 3% increase in the placebo
group. Median IgG levels in those receiving atacicept remained
above the lower limit of normal over the 52-week treatment
and only two patients reached the discontinuation threshold of
3 g/L. No serious infections were reported in these patients. The
incidence of infection was comparable regardless of the degree
of decline in IgG or IgM levels. In contrast, a trial of atacicept
in combination with MMF and corticosteroids in patients with
lupus nephritis was terminated prematurely due to rapid falls in
IgG levels after six patients were recruited.18 This decrease in
IgG started with the initiation of MMF and high-dose oral ster-
oids 2 weeks before atacicept (four patients) or placebo (two
patients) was given. Two of these atacicept-treated patients
developed pneumonia, one due to Haemophilus inﬂuenza and
one due to Legionella pneumophila before the trial was termi-
nated, although neither patient died.
The overall similarity in adverse events between the three
arms of the study, including serious events, is reassuring and
Table 2 Proportion of patients experiencing at least one adverse event (Safety Analysis Set)
Placebo
n=154
Atacicept 75 mg
n=157
Atacicept 150 mg
n=144
Adverse events, treatment and follow-up 123 (79.9) 131 (83.4) 120 (83.3)
Adverse events, treatment only 117 (76.0) 130 (82.8) 116 (80.6)
Adverse events leading to treatment discontinuation 17 (11.0) 14 (8.9) 16 (11.1)
Serious adverse events, treatment and follow-up 27 (17.5) 30 (19.1) 23 (16.0)
Serious adverse events, treatment only 21 (13.6) 23 (14.6) 20 (13.9)
Serious adverse events leading to treatment discontinuation 12 (7.8) 4 (2.5) 6 (4.2)
Infections, treatment and follow-up 83 (53.9) 97 (61.8) 85 (59.0)
Infections, treatment only 80 (51.9) 93 (59.2) 79 (54.9)
Upper respiratory tract infection 20 (13.0) 24 (15.3) 22 (15.3)
Urinary tract infection 15 (9.7) 18 (11.5) 20 (13.9)
Nasopharyngitis 10 (6.5) 20 (12.7) 15 (10.4)
Bronchitis 5 (3.2) 9 (5.7) 9 (6.3)
Sinusitis 10 (6.5) 6 (3.8) 4 (2.8)
Influenza 8 (5.2) 3 (1.9) 5 (3.5)
Serious infections, treatment and follow-up 11 (7.1) 13 (8.3) 11 (7.6)
Pneumonia 2 (1.3) 5 (3.2) 3 (2.1)
Upper respiratory tract infection – 2 (1.3) 2 (1.4)
Urinary tract infection 2 (1.3) 1 (0.6) –
Serious infections, treatment only 7 (4.5) 6 (3.8) 10 (6.9)
Pneumonia 1 (0.6) 3 (1.9) 3 (2.1)
Upper respiratory tract infection – 1 (0.6) 2 (1.4)
Urinary tract infection 1 (0.6) 1 (0.6) –
Deaths 0 (0) 0 (0) 2 (1.4)
All data are n (%).
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consistent with previous studies of atacicept in rheumatoid arth-
ritis, although the rate of total infections and serious infections
was slightly higher with atacicept 150 mg, as observed in the
rheumatoid arthritis19 and multiple sclerosis studies(unpublished
data). The rate of serious infectious in the BLISS 76 study (7%
and 7.3% in the 1 and 10 mg/kg arms, respectively) is virtually
identical to the 6.9% observed in the atacicept 150 mg arm of
the present study. In neither atacicept arm was the risk of
serious infection statistically signiﬁcantly increased compared
with the placebo arm. In the Exploratory Phase II/III SLE
Evaluation of Rituximab (EXPLORER) trial of rituximab in
patients with non-renal SLE,20 the rate of serious infections was
even higher (17% in the placebo group and 9.5% in the rituxi-
mab group), perhaps reﬂecting the more intensive use of gluco-
corticoids. These results suggest that contributing factors to the
deaths observed in our study may have included the underlying
disease, steroid therapy and delays in diagnosis and treatment.
The primary and main secondary efﬁcacy endpoints in this
trial were assessed using the BILAG assessment index. The ﬂare
rates seen in this study were in line with those previously
reported.21 Distinct differences in ﬂare rates and time to ﬂare
were seen between the treatment arms. Prevention of ﬂares is an
important clinically signiﬁcant outcome as the frequency of
ﬂares is correlated with disease progression and organ
damage.20
Atacicept is one of several B cell-directed therapies that have
been under investigation in SLE, which include anti-CD20
(rituximab), anti-BLyS (belimumab, blisibimod and tabalumab),
anti-CD22 (epratuzumab) and atacicept, which blocks BLyS and
APRIL. In the current trial, we examined whether atacicept
could prevent ﬂares in patients at high risk for a lupus ﬂare. We
selected patients who had recently had a lupus ﬂare that was
controlled by a relatively short course of glucocorticoids. In
contrast, the other therapies have been subjected to trial designs
intended to treat active disease. Given the different trial strat-
egies for each agent, and in the absence of any head-to-head
comparison, it is not known which of these approaches will
prove to have the most advantageous beneﬁt: risk ratio or, alter-
natively, whether different agents will be appropriate for differ-
ent purposes (eg, induction vs maintenance).
In conclusion, the primary endpoint of reducing the numbers
of SLE patients who had a new ﬂare was not met in the ataci-
cept 75 mg arm compared with placebo. The results with the
higher dose of 150 mg were more encouraging, but there are
concerns about the possible infection risk in the light of two
deaths in that arm. Treating patients with active lupus remains a
great challenge.
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